Use of Chimeric Antigen Receptor T Cells in Allogeneic Hematopoietic Stem Cell Transplantation | Zendy

Jun Li | Zendy; Xi Zhang | Zendy; Jiang F. Zhong | Zendy; Cheng Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of Chimeric Antigen Receptor T Cells in Allogeneic Hematopoietic Stem Cell Transplantation

Author(s) -

Jun Li,

Xi Zhang,

Jiang F. Zhong,

Cheng Zhang

Publication year - 2018

Publication title -

immunotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.127

H-Index - 48

eISSN - 1750-7448

pISSN - 1750-743X

DOI - 10.2217/imt-2018-0089

Subject(s) - chimeric antigen receptor , hematopoietic stem cell transplantation , stem cell , transplantation , haematopoiesis , immunology , antigen , chimera (genetics) , biology , cancer research , medicine , immunotherapy , microbiology and biotechnology , genetics , immune system , gene

The chimeric antigen receptor T (CAR-T) cells play an antileukemia role, and can be used to treat or prevent relapse by targeting minimal residual disease for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the infusion of allogeneic CAR-T cells may also cause graft-versus-host disease, which limited their applications during and after allo-HSCT. In this review, we discuss the clinical trials that applying CAR-T cells before allo-HSCT and the use of donor-derived CAR-T cells as conditioning regimen during allo-HSCT. At last, we analyzed the effect of donor-derived CAR-T cells on preventive infusion after allo-HSCT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research